Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Hyperimmune Globulins Intravenous (IV) or Subcutaneous (SC) bulk supplier for pharma manufacturers

Hyperimmune Globulins Intravenous (Iv) Or Subcutaneous (Sc) 100 mg/mL or 50 mg/mL Suppliers & Bulk Manufacturers

Available Forms: Intravenous (IV) or Subcutaneous (SC) Solution

Available Strengths: 100 mg/mL or 50 mg/mL

Reference Brands: Tetanus IG (TIG), Varicella Zoster IG, Cytogam,RhoGAM,Hepatitis B Immune Globulin (HBIG)(US)

Category: Plasma Products

Hyperimmune globulins IV provide passive immunity by supplying concentrated, pathogen-specific antibodies. They neutralize viruses or toxins, prevent infections, and support immune defense in exposed or immunocompromised individuals. Benefits include rapid protection, reduced disease severity, and enhanced immune response during post-exposure prophylaxis or treatment of infectious diseases.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide

Product Description: Hyperimmune globulins (IV), such as Cytogam or HBIG, are approved in the US by the FDA and in the EU via EMA for passive immunization against specific diseases like CMV, rabies, and hepatitis B. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews detailed submissions for safety and efficacy, while the EMA ensures compliance with regional quality standards. For guidance on dossier preparation, regulatory pathways, and market access strategies, visit PharmaTradz. Ensuring compliance is essential for timely approval and safe worldwide use, supporting effective disease prevention.

Hyperimmune Globulins Intravenous (Iv) Or Subcutaneous (Sc) — third party manufacturing & bulk supply

Hyperimmune Globulins Intravenous (Iv) Or Subcutaneous (Sc) 100 mg/mL or 50 mg/mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

What to include when you enquire

  • Destination market — determines which manufacturers hold the right site-level approvals
  • First order quantity and estimated annual volume
  • Whether you need a registration dossier or the product is already registered
  • Packaging, labelling and language requirements
  • Incoterms and required shelf life

Manufacturers of Hyperimmune Globulins Intravenous (Iv) Or Subcutaneous (Sc) listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.

Request a quote for Hyperimmune Globulins Intravenous (Iv) O... →
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Frequently Asked Questions

PharmaTradz connects buyers with GMP-certified third party and contract manufacturers of Hyperimmune Globulins Intravenous (IV) or Subcutaneous (SC) (reference brands: Tetanus IG (TIG), Varicella Zoster IG, Cytogam,RhoGAM,Hepatitis B Immune Globulin (HBIG)(US)). Manufacturers on the platform hold approvals including WHO-GMP, EU-GMP and USFDA at site level. Post a requirement with your volume and destination market to receive quotes.

Hyperimmune Globulins Intravenous (IV) or Subcutaneous (SC) is available for wholesale and bulk supply through verified exporters listed on PharmaTradz. Share your first order quantity, destination market and Incoterms in an RFQ and matched suppliers respond with pricing and lead times.

Hyperimmune Globulins Intravenous (IV) or Subcutaneous (SC) is available as Intravenous (IV) or Subcutaneous (SC) Solution in 100 mg/mL or 50 mg/mL. Other strengths and pack presentations can often be produced to order under a third party manufacturing arrangement. Availability for your market is confirmed at RFQ stage.

Yes — suppliers on PharmaTradz support bulk export with regulatory documentation such as COA, GMP certificates and CTD, EU-CTD or ACTD dossiers where available. Share your destination market in your RFQ and we match you to suppliers holding the right registrations to serve it.

Minimum order quantities vary by manufacturer, dosage form and whether the order is a stock supply or a dedicated third party manufacturing batch. Indian and Asian manufacturers typically accept lower MOQs than tier-1 global platforms. Submit your requirement and suppliers quote their MOQ alongside pricing.

Related Products

Marstacimab‑Hncq

Strength:
150 mg/mL

Form: injection (prefilled syringe)

Reference Brands: Hympavzi (USA)

View Details
Emicizumab‑Kxwh

Strength:
30 mg/mL, 60 mg/0.4 mL, 105 mg/0.7 mL

Form: Injection

Reference Brands: Hemlibra (USA/EU)

View Details
Concizumab-Mtci

Strength:
60 mg/1.5 mL, 150 mg/1.5 mL, 300 mg/3 mL

Form: Prefilled autoinjector

Reference Brands: Alhemo (USA/EU)

View Details
Fresh Frozen Plasma (Ffp) Powder For Reconstitution Or Liquid

Strength:
available in 200-250 mL units

Form: liquid units or lyophilized (freeze-dried) powder

Reference Brands: No specific brands

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.